Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide found throughout the nervous, immune, and GI systems. It binds VPAC1 and VPAC2 receptors, producing potent anti-inflammatory effects via cAMP signalling. It is studied for Chronic Inflammatory Response Syndrome (CIRS), mast cell activation syndrome, and long COVID.
Overview
Reconstitution Table (20 mL saline mL BAC water u2192 2 mg)
| Route | Dose | Frequency |
| Intranasal | 50 mcg | Twice daily |
| IV (clinical) | 2u20134 mcg/kg over 12 hr | Per clinical protocol |
For intranasal: dilute 2 mg in 20 mL saline u2192 100 mcg/mL. 50 mcg = 0.5 mL per dose. Use a nasal atomiser. Shake gently before use.
VIP intranasal is used in Shoemaker CIRS protocol. Should be preceded by eradication of biotoxin exposure. Research and clinical use only.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory cytokine modulation
- Bronchodilation
- Gut motility regulation
- Mast cell stabilisation
- CIRS symptom improvement (Shoemaker protocol)
Possible Side Effects
- Facial flushing (transient)
- Headache
- Nausea (uncommon)
- Aggravation without prior biotoxin removal (CIRS)
Storage Instructions
Lyophilized Powder
- Short-term (<3 months): Refrigerate at 2u00b0Cu20138u00b0C
- Long-term: Freeze at u221220u00b0C or lower
- Protect from light and moisture
- Allow vial to reach room temperature before opening
Reconstituted Solution
- Refrigerate at 2u00b0Cu20138u00b0C u2014 do not freeze
- Use within 28 days when reconstituted with BAC water
- Always use sterile technique when drawing doses
References
Delgado M et al. (2004)
Vasoactive intestinal peptide generates regulatory dendritic cells
View SourceImportant Note
This protocol guide is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before using any peptide compound.